Regeneron Pharmaceuticals (REGN) Assets Average (2010 - 2026)

Regeneron Pharmaceuticals' Assets Average history runs 17 years deep, the most recent figure standing at $40.7 billion for Q1 2026.

• On a quarterly basis, Assets Average rose 8.13% year-over-year to $40.7 billion in Q1 2026; TTM through Mar 2026 was $40.7 billion, a 8.13% increase from a year earlier, with the FY2025 full-year figure at $39.2 billion, up 10.56% from the prior year.
• Assets Average grew to $40.7 billion in Q1 2026 per REGN's latest filing, from $40.4 billion in the prior quarter.
• Across five years, Assets Average topped out at $40.7 billion in Q1 2026 and bottomed at $25.9 billion in Q1 2022.
• The 5-year median for Assets Average is $33.7 billion (2024), against an average of $33.6 billion.
• Across the five-year window, Assets Average surged 48.23% in 2022 and gained 6.61% in 2025, its largest moves.
• Year by year, Assets Average stood at $28.4 billion in 2022, then climbed by 14.68% to $32.6 billion in 2023, then increased by 15.26% to $37.6 billion in 2024, then gained by 7.35% to $40.4 billion in 2025, then rose by 0.87% to $40.7 billion in 2026.
• Per Business Quant, the three latest REGN Assets Average figures stand at $40.7 billion (Q1 2026), $40.4 billion (Q4 2025), and $39.2 billion (Q3 2025).